Clinical data | |
---|---|
Other names | 6-OH-DOPA; 6-OHDOPA |
Drug class | Catecholaminergic neurotoxin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C9H11NO5 |
Molar mass | 213.189 g·mol−1 |
3D model (JSmol) | |
| |
|
6-Hydroxydopa (6-OH-DOPA; 6-OHDOPA) is a catecholaminergic neurotoxin that damages noradrenergic and dopaminergic neurons and is used in scientific research.[1][2][3] It is a precursor and prodrug of 6-hydroxydopamine (6-OHDA).[1][2][3] The drug is a derivative of levodopa (L-DOPA).[1][2][3] It has certain advantages over 6-OHDA, such as the ability to cross the blood–brain barrier into the central nervous system and hence the ability to be administered systemically rather than directly into the brain.[1][2][3] 6-OH-DOPA was first described in the scientific literature by 1969.[4]